ARNUITY ELLIPTA

Peak

fluticasone furoate

NDAINHALATIONPOWDER
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

anti-inflammatory activity. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is approximately 29.9 times that of dexamethasone and 1.7 times that of fluticasone propionate. The clinical relevance of these findings is unknown. The…

Indications (1)

Clinical Trials (5)

NCT04923347Phase 4Completed

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Started Jun 2023
229 enrolled
Pulmonary Disease, Chronic Obstructive
NCT05535972Phase 4Completed

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Started Oct 2022
463 enrolled
Pulmonary Disease, Chronic Obstructive
NCT04937387Phase 3Completed

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Started Jul 2021
359 enrolled
Asthma
NCT03376932Phase 3Withdrawn

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

Started Jan 2019
0
Asthma
NCT03478683Phase 4Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Started Jun 2018
729 enrolled
Pulmonary Disease, Chronic Obstructive